The academic, federal regulatory, and patient advocacy communities are collaborating to develop consensus endpoints for NF1 trials and to establish a clear pathway for developing measurement tools to support drug approvals for NF-associated tumors, which ultimately will contribute to improved outcomes for NF1-associated gliomas. This evidence concerns the gene NF1 and central nervous system cancer.